Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid for Skin and Skin Structure Infections

Trius Therapeutics Completes Enrollment in Second Phase 3 Trial of Tedizolid
for Skin and Skin Structure Infections

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and
development of innovative antibiotics for life-threatening infections,
announced today that it has reached its enrollment objective of 658 patients
in the last of its two Phase 3 clinical trials of tedizolid phosphate (TR-701)
for the treatment of acute bacterial skin and skin structure infections

The pivotal Phase 3 trial, designated ESTABLISH 2, examines the efficacy and
safety of a six-day course of tedizolid administered once a day versus a
10-day course of linezolid (Zyvox^®) administered twice a day in patients
recruited across sites in North and South America, Europe, Australia, New
Zealand and South Africa. For both tedizolid phosphate and linezolid, drug was
initially administered as an intravenous (IV) infusion with the option to
switch to oral therapy after the initial day of therapy.

"As with our ESTABLISH 1 study, ESTABLISH 2 was designed to prepare tedizolid
for registration globally by capturing both the new and former FDA endpoints
as well as the European endpoints for ABSSSI," said Jeffrey Stein, Ph.D.,
President and Chief Executive Officer at Trius. "We remain on schedule to
report top-line results from this study in early 2013. The tedizolid clinical
program reflects our commitment to bring safe, well-tolerated and convenient
therapies to people with life-threatening infections."

Last year, Trius completed its ESTABLISH 1 study, testing the oral dosing of
tedizolid under the same trial design and endpoints as in ESTABLISH 2. The
trial achieved all primary and secondary efficacy outcomes and showed
significant safety and tolerability improvements versus linezolid.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of innovative antibiotics for
life-threatening infections. The Company's lead investigational drug,
tedizolid phosphate, is a once daily, IV and orally administered second
generation oxazolidinone in Phase 3 clinical development for the treatment of
serious gram-positive infections, including those caused by
methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with
Bayer HealthCare for the development and commercialization of tedizolid
phosphate outside of the U.S., Canada and the European Union. In addition to
the Company's tedizolid phosphate clinical program, Trius has initiated
IND-enabling studies for its Gyrase-B development candidate with potent
activity against Gram-negative bacterial pathogens including multi-drug
resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The
Gyrase-B program is one of the two preclinical programs supported by federal
contracts. For more information, visit

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, statements regarding the expected timing of
Trius' reporting of top-line results from the Establish 2 study. Risks that
contribute to the uncertain nature of the forward-looking statements include:
the accuracy of Trius' estimates regarding expenses, future revenues and
capital requirements; the success and timing of Trius' preclinical studies and
clinical trials; regulatory developments in the United States and foreign
countries; changes in Trius' plans to develop and commercialize its product
candidates; Trius' ability to obtain additional financing; Trius' ability to
obtain and maintain intellectual property protection for its product
candidates; and the loss of key scientific or management personnel. These and
other risks and uncertainties are described more fully in Trius' most recently
filed SEC documents, including its Form 10-K, Forms 10-Q and other documents
filed with the United States Securities and Exchange Commission, including
those factors discussed under the caption "Risk Factors" in such filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Trius undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
Press spacebar to pause and continue. Press esc to stop.